This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Original article
Yamamura, T. et al. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar. Mult. Scler. Relat. Disord. https://doi.org/h6j4 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lemprière, S. Long-term safety of satralizumab in NMOSD. Nat Rev Neurol 18, 510 (2022). https://doi.org/10.1038/s41582-022-00709-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-022-00709-7